ストックスクリーナーアプリを入手
36.13
1.87%
-0.69
プレマーケット:
35.90
-0.23
-0.64%
Roivant Sciences Ltd (ROIV) 最新ニュース
Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging? - Insider Monkey
Cantor Fitzgerald reiterates Roivant Sciences stock rating By Investing.com - Investing.com Canada
Roivant Sciences Ltd. (ROIV) Stock Forecasts - finance.yahoo.com
ROIV Looks 361.0% Overvalued on GF Value™ - GuruFocus
Roivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance UK
Why Is Immunovant Stock Falling Wednesday?Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT) - Benzinga
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss - Yahoo Finance
Roivant slips on trial setback for Immunovant (ROIV:NASDAQ) - Seeking Alpha
A skin-lupus drug study missed its main goal. Its developer plans to stop testing it. - Stock Titan
Behavioral Patterns of ROIV and Institutional Flows - Stock Traders Daily
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History - ca.finance.yahoo.com
Roivant (ROIV) CAO uses 3,880 shares to cover RSU taxes - Stock Titan
Form 4 Roivant Sciences Ltd. For: 22 September By Investing.com - Investing.com Australia
Roivant Sciences (ROIV) CFO now holds 269,681 shares after RSU tax withholding - Stock Titan
Why Roivant Sciences (ROIV) Is Back In The Spotlight - simplywall.st
Transcript : Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2026, Sep-22-2026 12 - marketscreener.com
Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test - finance.yahoo.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: Analyzing a 20% Potential Upside Amid Biotech Innovation - DirectorsTalk Interviews
Did Positive PH ILD Trial Data Just Shift Roivant Stock Investment Narrative? - simplywall.st
Roivant Sciences (ROIV) director receives new 2027-vesting equity grant - Stock Titan
Roivant Sciences (ROIV) director now holds 8.97M shares - Stock Titan
New stock awards for Roivant Sciences (ROIV) director vest in 2027 - Stock Titan
Roivant Sciences (ROIV) grants director stock awards vesting in 2027 - Stock Titan
Roivant Sciences (ROIV) gives director new options and RSUs - Stock Titan
Director at Roivant (ROIV) receives new stock awards - Stock Titan
What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data? - finance.yahoo.com
Director Melissa Epperly Sells 4,938 Shares of Roivant Sciences Ltd (ROIV) - GuruFocus
Roivant Sciences (NASDAQ: ROIV) director sells 4,938 shares under 10b5-1 plan - Stock Titan
Roivant Sciences (ROIV) director sells 5,112 shares under pre-set plan - Stock Titan
ROIV Initiates Coverage by Stifel -- Price Target Announced at $51 - GuruFocus
Roivant Sciences Initiated at Buy by Stifel - Moomoo
Stifel initiates Roivant Sciences stock with buy rating, $51 target By Investing.com - Investing.com South Africa
Stifel initiates Roivant Sciences stock with buy rating, $51 target - Investing.com
Roivant Sciences (ROIV) director lines up $930K stock sale - Stock Titan
Roivant Sciences (NASDAQ: ROIV) officer to sell 5,112 shares - Stock Titan
Why Roivant Sciences (ROIV) Stock Is Down Today - quiverquant.com
Roivant Sciences Director Melissa B. Epperly Forfeits 2,179 Shares at $40.94 Each (NASDAQ: ROIV) - Kalkine Media
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses stock to cover tax bill - Stock Titan
Roivant Sciences Ltd. (ROIV) Stock Analysis: High Analyst Confidence with a 12.58% Upside Potential - DirectorsTalk Interviews
Roivant Sciences (ROIV) director uses shares to cover taxes - Stock Titan
ROIV gains commercial footing with LISRAYA appr... - Pluang
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (ROIV)’s Pulmonary Hypertension Breakthrough Could Transform Its Growth Story - Yahoo Finance
(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Roivant Sciences (ROIV) Could Be 308% Overvalued Following Phase 2 Mosliciguat Data - simplywall.st
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Roivant Sciences (ROIV) director sells stock under preset plan - Stock Titan
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILDSlideshow (NASDAQ:ROIV) 2026-09-10 - Seeking Alpha
ROIV: FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook - TradingView
Did Phase 2 Trial Win Just Shift Roivant Sciences (ROIV) Investment Narrative? - simplywall.st
ROIV: Robust pipeline advances and strong financials set the stage for multiple upcoming launches - TradingView
Roivant at Citi summit: cash-rich biotech leans on three pillars - Investing.com India
Why Did Roivant (NASDAQ:ROIV) Shares Surge on Study Results? - Kalkine Media
Roivant Sciences Company Profile & Introduction - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $46 to $55 - Moomoo
ROIV Maintains Buy Rating -- Price Target Raised to $55 - GuruFocus
Roivant Reports 56.3% Placebo-Adjusted PVR Reduction In Phase 2 Mosliciguat PH-ILD Study, Starts Phase 3 PHrontier Trial - Pulse 2.0
Guggenheim raises Roivant Sciences stock price target on trial data By Investing.com - Investing.com Australia
TD Cowen raises Roivant Sciences stock price target on trial data - Investing.com Australia
H.C. Wainwright raises Roivant Sciences price target on trial data - investing.com
Guggenheim raises Roivant Sciences stock price target on trial data - Investing.com
Roivant Sciences Stock Rallies 20% On Positive Phase 2 Trial Results For Pulmovant Drug - TIKR.com
1.11%
1.38%
大文字化:
|
ボリューム (24 時間):